Our corporate responsibility program
At Ultragenyx, our corporate responsibility strategy helps us identify, manage and communicate on topics relevant to our business and stakeholders and is structured around six key pillars:
- Innovation
- Patients
- People
- Communities
- Planet
- Governance
By focusing on these pillars, we strive to make a meaningful difference in the lives of those affected by rare and ultra-rare diseases.
To learn more about our corporate responsibility priorities,download the Materiality Assessment
Our 2024 Impact Report
Our 2024 Impact Report covers our approach to corporate responsibility and highlights our ongoing commitment to transparency.
The report details:
- Our innovative approach to drug development
- Efforts towards providing equitable access to our medicines and improved care for people impacted by the rare diseases we study
- Our commitment to creating an inclusive workplace culture
- Our philanthropic support for community initiatives
- Our efforts to reduce our environmental footprint
- Our emphasis on strong corporate governance and a culture of integrity
Our strategic pillars
Commitment
We are a next-generation rare disease company committed to developing and delivering transformative treatments where none exist.
Aspiration
To optimize and accelerate the field of rare disease drug research and development (R&D).
participants representing more than 120 organizations have attended our Rare BootcampTM since 2017.
locations with clinical studies in 21 countries as of Dec 31, 2024.
investigational therapies in late-stage development
for the treatment of osteogenesis imperfecta (OI), Angelman syndrome (AS), Wilson disease (WD), Sanfilippo syndrome type A (MPS IIIA), glycogen storage disease type la (GSDla), and ornithine transcarbamylase (OTC) deficiency.
Commitment
We are committed to supporting the rare disease community through our efforts to develop novel therapies, share our science and expertise, achieve broad access to screening and treatment, and partner with policymakers for meaningful change.
Aspiration
To achieve meaningful benefit for people living with rare diseases by delivering on the promise of our science and our therapies.
patients in 50 countries have been approved for access to Ultragenyx treatments through various global expanded access and patient assistance programs since 2013.
patient advocacy conferences, meetings and townhalls attended worldwide in 2024.
Commitment
We are committed to working to maintain an inclusive, safe and healthy environment. We are also committed to fair and equitable compensation practices that are transparent and free from bias.
Aspiration
To be an inclusive, sought-after company where employees come first and feel motivated to bring the best versions of themselves to work each day, knowing they are making a difference in the lives of the rare disease community.
employee development workshops offered in 2024.
employee engagement score in 2024.*
students hosted across our Emerging Talent programs in 2024.
*A subset of the employee engagement survey—focused on employee pride in our company, whether an employee would recommend Ultragenyx as a good place to work, whether an employee experiences a feeling of personal accomplishment from their work and the employee’s intent to remain with us—is used to calculate an employee engagement score.
Commitment
We are committed to supporting initiatives that provide meaningful impact for the rare disease community, public health and access to care, Science, Technology, Engineering, Arts and Mathematics (STEAM) education, and local, at-risk communities.
Aspiration
To make a positive impact in the communities where we operate and beyond.
in charitable donations, independent medical education and health-related grants across 24 countries in 2024.
volunteer hours recorded by eligible employees in 2024.
service projects completed around the world during our 2nd Annual Days of Service in 2024.
Commitment
We are committed to implementing an environmental strategy that helps to minimize our environmental footprint across our business.
Aspiration
To conduct business in an environmentally responsible manner and strive to continuously improve our performance to benefit our employees, patient and physician communities, the localities where we work, and the environment.
renewable electricity procured at our Novato, CA headquarters since 2021.
pounds of laboratory waste diverted from incineration in 2024 through our recycling partnerships.
level My Green Lab certification achieved at our Translational Sciences lab in Novato, California.
Commitment
The foundation of our purpose to lead the future of rare disease medicine is built upon our commitments to strong corporate governance, ethics and integrity, compliance, data protection and security and responsible procurement.
Aspiration
Through strong corporate governance and a culture of integrity, we seek to prevent significant issues before they occur and foster an environment where issues can be disclosed without the threat of retaliation.
requirements for our directors and named executive officers.
attendance of board and committee meetings by our current directors in 2024.
Resources
Awards and recognitions
Discover more about Ultragenyx:
Grants and contributions
Ultragenyx supports initiatives that provide impactful resources for the rare disease community.
View grants and charitable contributions